中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性HBV感染与代谢相关脂肪性肝病: 已知与未知

耿楠 倪文婧 芮法娟 李婕

引用本文:
Citation:

慢性HBV感染与代谢相关脂肪性肝病: 已知与未知

DOI: 10.12449/JCH240301
基金项目: 

国家自然科学基金面上项目 (819705457)

国家自然科学基金面上项目 (82170609)

江苏省自然科学基金面上项目 (BK20231118)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:耿楠、倪文婧和芮法娟负责撰写文章;李婕负责审校。
详细信息
    通信作者:

    李婕, lijier@nju.edu.cn (ORCID: 0000-0003-0973-8645)

Chronic hepatitis B virus infection and metabolic associated fatty liver disease: The known and unknown aspects

Research funding: 

General Project of National Natural Science Foundation of China (819705457);

General Project of National Natural Science Foundation of China (82170609);

General Project of National Science Foundation of Jiangsu Province (BK20231118)

More Information
    Corresponding author: LI Jie, lijier@nju.edu.cn (ORCID: 0000-0003-0973-8645)
  • 摘要: 慢性HBV感染是全球病毒性肝炎疾病负担的主要原因。由于生活方式和饮食习惯的改变,代谢相关脂肪性肝病(MAFLD)的发病率不断上升,已成为全球第一大慢性肝病。慢性HBV感染合并MAFLD在临床上越来越常见,代谢因素而非病毒因素是慢性HBV感染合并MAFLD的主要原因。在疾病发展进程中,炎症、纤维化而非脂肪变性是合并患者发展为肝硬化、肝细胞癌的主要影响因素。对于慢性HBV感染和MAFLD同时存在的患者,抗病毒和代谢因素的联合管理至关重要。本文就慢性HBV感染合并MAFLD的相互作用、预后转归和临床管理等热点话题进行讨论。

     

  • [1] LIU Z, LIN C, MAO X, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3 740 studies and 231 million people[J]. Gut, 2023, 72( 12): 2354- 2363. DOI: 10.1136/gutjnl-2023-330691.
    [2] LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4( 5): 389- 398. DOI: 10.1016/S2468-1253(19)30039-1.
    [3] HUI R, SETO WK, CHEUNG KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study[J]. J Viral Hepat, 2018, 25( 1): 97- 104. DOI: 10.1111/jvh.12766.
    [4] WANG MM, WANG GS, SHEN F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci, 2014, 59( 10): 2571- 2579. DOI: 10.1007/s10620-014-3180-9.
    [5] HUANG SC, SU TH, TSENG TC, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion[J]. Clin Gastroenterol Hepatol, 2023. DOI: 10.1016/j.cgh.2023.09.040.[ Online ahead of print]
    [6] MAK LY, HUI RW, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73( 4): 800- 806. DOI: 10.1016/j.jhep.2020.05.040.
    [7] LI J, YANG HI, YEH ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224( 2): 294- 302. DOI: 10.1093/infdis/jiaa739.
    [8] MAO X, CHEUNG KS, PENG C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2023, 77( 5): 1735- 1745. DOI: 10.1002/hep.32792.
    [9] TONG X, SONG Y, YIN S, et al. Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease[J]. Chin Med J(Engl), 2022, 135( 14): 1653- 1663. DOI: 10.1097/CM9.0000000000002310.
    [10] JOO EJ, CHANG Y, YEOM JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 65( 3): 828- 835. DOI: 10.1002/hep.28917.
    [11] ZHENG Q, ZOU B, WU Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54( 9): 1100- 1109. DOI: 10.1111/apt.16595.
    [12] ZHU L, JIANG J, ZHAI X, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study[J]. Liver Int, 2019, 39( 1): 70- 80. DOI: 10.1111/liv.13933.
    [13] ZHOU R, YANG L, ZHANG B, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis[J]. J Viral Hepat, 2023, 30( 10): 793- 802. DOI: 10.1111/jvh.13872.
    [14] KHALILI M, KLEINER DE, KING WC, et al. Hepatic steatosis and steatohepatitis in a large north american cohort of adults with chronic hepatitis B[J]. Am J Gastroenterol, 2021, 116( 8): 1686- 1697. DOI: 10.14309/ajg.0000000000001257.
    [15] HUANG Y, GAN Q, LAI R, et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients[J]. Front Cell Infect Microbiol, 2021, 11: 733348. DOI: 10.3389/fcimb.2021.733348.
    [16] CHOI H, BROUWER WP, ZANJIR W, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B[J]. Hepatology, 2020, 71( 2): 539- 548. DOI: 10.1002/hep.30857.
    [17] PELEG N, ISSACHAR A, SNEH ARBIB O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load[J]. JHEP Rep, 2019, 1( 1): 9- 16. DOI: 10.1016/j.jhepr.2019.02.002.
    [18] MAK LY, HUI RW, FUNG J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection[J]. Hepatol Int, 2021, 15( 4): 901- 911. DOI: 10.1007/s12072-021-10218-2.
    [19] WONG YJ, NGUYEN VH, YANG HI, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis[J]. Clin Mol Hepatol, 2023, 29( 3): 705- 720. DOI: 10.3350/cmh.2023.0004.
    [20] JIN X, CHEN YP, YANG YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J]. PLoS One, 2012, 7( 3): e34198. DOI: 10.1371/journal.pone.0034198.
    [21] CHEN J, WANG ML, LONG Q, et al. High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B[J]. Hepatobiliary Pancreat Dis Int, 2017, 16( 4): 370- 374. DOI: 10.1016/S1499-3872(16)60144-3.
    [22] CHARATCHAROENWITTHAYA P, PONGPAIBUL A, KAOSOMBATWATTANA U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response[J]. Liver Int, 2017, 37( 4): 542- 551. DOI: 10.1111/liv.13271.
    [23] CHEN YC, JENG WJ, HSU CW, et al. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study[J]. BMC Gastroenterol, 2020, 20( 1): 146. DOI: 10.1186/s12876-020-01289-w.
    [24] LI J, LE AK, CHAUNG KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients[J]. Liver Int, 2020, 40( 5): 1052- 1061. DOI: 10.1111/liv.14415.
    [25] PLAUTH M, BERNAL W, DASARATHY S, et al. ESPEN guideline on clinical nutrition in liver disease[J]. Clin Nutr, 2019, 38( 2): 485- 521. DOI: 10.1016/j.clnu.2018.12.022.
    [26] HUANG SC, LIU CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives[J]. Clin Mol Hepatol, 2023, 29( 2): 320- 331. DOI: 10.3350/cmh.2022.0422.
  • 加载中
计量
  • 文章访问数:  239
  • HTML全文浏览量:  63
  • PDF下载量:  106
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-12-30
  • 录用日期:  2024-01-28
  • 出版日期:  2024-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回